查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1888637

全球血栓症藥物市場：市場規模、佔有率和趨勢分析（按疾病類型、藥物類別、分銷管道和地區分類），細分市場預測（2025-2033 年）

Thrombosis Drugs Market Size, Share & Trends Analysis Report By Disease Type (Deep Vein Thrombosis, Pulmonary Embolism), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血栓症藥物：市場概覽

2024年全球血栓症藥物市場規模估計為261.1億美元，預計2033年將達523億美元。

預計2025年至2033年，該市場將以8.03%的複合年成長率成長。推動該市場成長的主要因素是全球心血管疾病（CVD）的高發生率。心臟病、中風和靜脈血栓栓塞症（VTE）等疾病的增加，正在推動對有效抗凝血治療的需求。

全球人口老化也是推動市場成長的因素之一，因為老年人罹患血栓症及其併發症的風險更高。抗凝血治療技術的進步，包括更安全、更方便的口服藥物，正在改善患者的治療效果，並促進其廣泛應用。此外，肥胖、糖尿病和高血壓等文明病的日益流行，人們對血栓症風險的認知不斷提高，以及醫療保健支出的成長，再加上其他因素，持續支撐著市場的擴張。

產品創新和監管核准正在推動血栓症治療產業的發展，拓展治療選擇，增強臨床醫師的信心。近年來，藥物和醫療設備領域取得了顯著進展，例如快速且方便的溶栓藥物和改良的口服抗凝血劑，這些都提高了治療效果，簡化了給藥方式，促進了臨床應用，並支持了市場成長。例如，2025年3月，美國食品藥物管理局（FDA）核准了基因治療藥物TNKase用於治療急性缺血性腦中風（AIS）。 TNKase大劑量投藥，相較於標準藥物Activase（需在靜脈大劑量投藥後持續輸注60分鐘），給藥較快速方便。

由國際血栓與止血學會 (ISTH) 組織的「世界血栓症日」等全球宣傳活動，強調了預防和早期發現血栓症的重要性，從而間接支持了血栓症治療市場。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：血栓症藥物市場：影響因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTLE分析
    • 管道分析

第4章血栓症藥物市場：依疾病類型分類的業務分析

  • 按疾病類型分類的市場佔有率（2024 年和 2033 年）
  • 按疾病類型分類的市場規模預測和趨勢分析（2021-2033 年）
  • 深層靜脈栓塞症
  • 肺動脈栓塞
  • 心房顫動

第5章血栓症藥物市場：按藥物類別分類的業務分析

  • 按藥物類別分類的市場佔有率（2024 年和 2033 年）
  • 按藥物類別分類的市場規模預測和趨勢分析（2021-2033 年）
  • Xa因子抑制劑
  • 凝血酶抑制劑
  • 肝素
  • P2Y12血小板受體抑制劑
  • 其他

第6章血栓症藥物市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 按分銷管道分類的市場規模預測和趨勢分析（2021-2033）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章血栓症藥物市場：區域估算與趨勢分析

  • 按地區分類的市場佔有率分析（2024 年和 2033 年）
  • 市場概覽：按地區
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業對外使用
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Bristol-Myers Squibb Company
    • Johnson &Johnson
    • Boehringer Ingelheim International GmbH
    • SANOFI
    • AstraZeneca
    • Pfizer Inc.
    • CSL
    • Novo Nordisk A/S
    • Takeda Pharmaceutical Company Limited
    • Ionis Pharmaceuticals
    • Grifols, SA
    • Aspen Holdings
Product Code: GVR-4-68040-119-4

Thrombosis Drugs Market Summary

The global thrombosis drugs market size was estimated at USD 26.11 billion in 2024 and is projected to reach USD 52.30 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The growth of this market is primarily driven by the high prevalence of cardiovascular diseases (CVDs) worldwide, as conditions such as heart attack, stroke, and venous thromboembolism (VTE) increase the demand for effective anticoagulant therapies.

An aging global population further contributes to market growth, since older adults are more susceptible to thrombosis and related complications. Advances in anticoagulant therapies, including safer and more convenient oral options, improve patient outcomes and encourage wider adoption. In addition, the rising prevalence of lifestyle-related diseases such as obesity, diabetes, and hypertension, combined with growing awareness of thrombosis risks and increased healthcare expenditure, continues to support sustained market expansion.

Product innovation and regulatory approvals drive the thrombosis drugs industry by expanding treatment options and raising clinician confidence. Recent drug and device advances, including faster, easier-to-administer clot-dissolving medicines and improved oral anticoagulants, make treatment more effective and simpler to deliver, which supports market growth by increasing clinical uptake. For instance, in March 2025, Genetech's TNKase, a clot-dissolving agent, received the U.S. Food and Drug Administration (FDA) approval for treating acute ischemic stroke (AIS). It is delivered as a single five-second intravenous (IV) bolus, providing a quicker and simpler option than the standard Activase, which requires an IV bolus followed by a 60-minute infusion.

Global awareness initiatives, such as World Thrombosis Day, organized by the International Society on Thrombosis and Hemostasis (ISTH), help to highlight the importance of thrombosis prevention and early detection, thereby indirectly supporting the thrombosis drugs market.

Global Thrombosis Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thrombosis drugs market report based on disease type, drug class, distribution channel, and region:

  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Factor Xa Inhibitors
  • Thrombin Inhibitors
  • Heparins
  • P2Y12 Platelet Inhibitors
  • Others
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Thrombosis Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Thrombosis Drugs Market: Disease Type Business Analysis

  • 4.1. Disease Type Market Share, 2024 & 2033
  • 4.2. Disease Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
  • 4.4. Deep Vein Thrombosis
    • 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pulmonary Embolism
    • 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Atrial Fibrillation
    • 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Thrombosis Drugs Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2033
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 5.4. Factor Xa Inhibitors
    • 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Thrombin Inhibitors
    • 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Heparins
    • 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 5.7. P2Y12 Platelet Inhibitors
    • 5.7.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Thrombosis Drugs Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Thrombosis Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 7.4. North America
    • 7.4.1. North America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Disease Prevalence
      • 7.4.2.3. Regulatory Framework/Reimbursement Framework
      • 7.4.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Disease Prevalence
      • 7.4.3.3. Regulatory Framework/Reimbursement Framework
      • 7.4.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Disease Prevalence
      • 7.4.4.3. Regulatory Framework/Reimbursement Framework
      • 7.4.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Disease Prevalence
      • 7.5.2.3. Regulatory Framework/Reimbursement Framework
      • 7.5.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Disease Prevalence
      • 7.5.3.3. Regulatory Framework/Reimbursement Framework
      • 7.5.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Disease Prevalence
      • 7.5.4.3. Regulatory Framework/Reimbursement Framework
      • 7.5.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Disease Prevalence
      • 7.5.5.3. Regulatory Framework/Reimbursement Framework
      • 7.5.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Disease Prevalence
      • 7.5.6.3. Regulatory Framework/Reimbursement Framework
      • 7.5.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Disease Prevalence
      • 7.5.7.3. Regulatory Framework/Reimbursement Framework
      • 7.5.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Disease Prevalence
      • 7.5.8.3. Regulatory Framework/Reimbursement Framework
      • 7.5.8.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Disease Prevalence
      • 7.5.9.3. Regulatory Framework/Reimbursement Framework
      • 7.5.9.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Disease Prevalence
      • 7.6.2.3. Regulatory Framework/Reimbursement Framework
      • 7.6.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Disease Prevalence
      • 7.6.3.3. Regulatory Framework/Reimbursement Framework
      • 7.6.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Disease Prevalence
      • 7.6.4.3. Regulatory Framework/Reimbursement Framework
      • 7.6.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Disease Prevalence
      • 7.6.5.3. Regulatory Framework/Reimbursement Framework
      • 7.6.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Disease Prevalence
      • 7.6.6.3. Regulatory Framework/Reimbursement Framework
      • 7.6.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Disease Prevalence
      • 7.6.7.3. Regulatory Framework/Reimbursement Framework
      • 7.6.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Disease Prevalence
      • 7.7.2.3. Regulatory Framework/Reimbursement Framework
      • 7.7.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Disease Prevalence
      • 7.7.3.3. Regulatory Framework/Reimbursement Framework
      • 7.7.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Disease Prevalence
      • 7.8.2.3. Regulatory Framework/Reimbursement Framework
      • 7.8.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Disease Prevalence
      • 7.8.3.3. Regulatory Framework/Reimbursement Framework
      • 7.8.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Disease Prevalence
      • 7.8.4.3. Regulatory Framework/Reimbursement Framework
      • 7.8.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Disease Prevalence
      • 7.8.5.3. Regulatory Framework/Reimbursement Framework
      • 7.8.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bristol-Myers Squibb Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Johnson & Johnson
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Boehringer Ingelheim International GmbH
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. SANOFI
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. CSL
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Novo Nordisk A/S
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Takeda Pharmaceutical Company Limited
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Ionis Pharmaceuticals
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Grifols, S.A.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Aspen Holdings
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global thrombosis drugs market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 5 Global thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 6 Global thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America thrombosis drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 9 North America thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 10 North America thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 12 U.S thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 13 U.S thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 15 Canada thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 16 Canada thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 18 Mexico thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 19 Mexico thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe thrombosis drugs market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 22 Europe thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 23 Europe thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 25 UK thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 26 UK thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 28 Germany thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 29 Germany thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 31 France thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 France thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 34 Italy thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 Italy thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 37 Spain thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 38 Spain thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Denmark thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 40 Denmark thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 41 Denmark thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Sweden thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 43 Sweden thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 44 Sweden thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Norway thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 46 Norway thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 47 Norway thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific thrombosis drugs market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 53 Japan thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 54 Japan thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 56 China thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 57 China thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 59 India thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 60 India thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 62 Australia thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 63 Australia thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 65 South Korea thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 66 South Korea thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 68 Thailand thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 69 Thailand thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America thrombosis drugs market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 72 Latin America thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 73 Latin America thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 75 Brazil thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 76 Brazil thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 78 Argentina thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 79 Argentina thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa thrombosis drugs market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 85 South Africa thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 86 South Africa thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 91 UAE thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 92 UAE thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait thrombosis drugs market, by disease type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait thrombosis drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 95 Kuwait thrombosis drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Thrombosis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Thrombosis drugs market dynamics
  • Fig. 12 Thrombosis drugs market: Porter's five forces analysis
  • Fig. 13 Thrombosis drugs market: PESTLE analysis
  • Fig. 14 Thrombosis drugs market: Disease type movement analysis
  • Fig. 15 Thrombosis drugs market: Disease type outlook and key takeaways
  • Fig. 16 Deep vein thrombosis market estimates and forecast, 2021 - 2033
  • Fig. 17 Pulmonary embolism market estimates and forecast, 2021 - 2033
  • Fig. 18 Atrial fibrillation market estimates and forecast, 2021 - 2033
  • Fig. 19 Thrombosis drugs market: Drug Class movement analysis
  • Fig. 20 Thrombosis drugs market: Drug Class outlook and key takeaways
  • Fig. 21 Factor Xa inhibitors market estimates and forecast, 2021 - 2033
  • Fig. 22 Thrombin inhibitors market estimates and forecast, 2021 - 2033
  • Fig. 23 Heparins market estimates and forecast, 2021 - 2033
  • Fig. 24 P2Y12 platelet inhibitors market estimates and forecast, 2021 - 2033
  • Fig. 25 Others market estimates and forecast, 2021 - 2033
  • Fig. 26 Thrombosis drugs market: Distribution channel movement analysis
  • Fig. 27 Thrombosis drugs market: Distribution channel outlook and key takeaways
  • Fig. 28 Hospital Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 29 Retail pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 30 Online Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 31 Thrombosis drugs market: Regional movement analysis
  • Fig. 32 Thrombosis drugs market: Regional outlook and key takeaways
  • Fig. 33 North America market estimates and forecast, 2021 - 2033
  • Fig. 34 U.S. market estimates and forecast, 2021 - 2033
  • Fig. 35 Canada market estimates and forecast, 2021 - 2033
  • Fig. 36 Mexico market estimates and forecast, 2021 - 2033
  • Fig. 37 Europe market estimates and forecast, 2021 - 2033
  • Fig. 38 UK market estimates and forecast, 2021 - 2033
  • Fig. 39 Germany market estimates and forecast, 2021 - 2033
  • Fig. 40 France market estimates and forecast, 2021 - 2033
  • Fig. 41 Italy market estimates and forecast, 2021 - 2033
  • Fig. 42 Spain market estimates and forecast, 2021 - 2033
  • Fig. 43 Denmark market estimates and forecast, 2021 - 2033
  • Fig. 44 Sweden market estimates and forecast, 2021 - 2033
  • Fig. 45 Norway market estimates and forecast, 2021 - 2033
  • Fig. 46 Asia Pacific market estimates and forecast, 2021 - 2033
  • Fig. 47 Japan market estimates and forecast, 2021 - 2033
  • Fig. 48 China market estimates and forecast, 2021 - 2033
  • Fig. 49 India market estimates and forecast, 2021 - 2033
  • Fig. 50 Australia market estimates and forecast, 2021 - 2033
  • Fig. 51 South Korea market estimates and forecast, 2021 - 2033
  • Fig. 52 Thailand market estimates and forecast, 2021 - 2033
  • Fig. 53 Latin America market estimates and forecast, 2021 - 2033
  • Fig. 54 Brazil market estimates and forecast, 2021 - 2033
  • Fig. 55 Argentina market estimates and forecast, 2021 - 2033
  • Fig. 56 Middle East & Africa market estimates and forecast, 2021 - 2033
  • Fig. 57 South Africa market estimates and forecast, 2021 - 2033
  • Fig. 58 Saudi Arabia market estimates and forecast, 2021 - 2033
  • Fig. 59 UAE market estimates and forecast, 2021 - 2033
  • Fig. 60 Kuwait market estimates and forecast, 2021 - 2033
  • Fig. 61 Company categorization
  • Fig. 62 Company market position analysis
  • Fig. 63 Strategic framework